AU Patent

AU2018308116A1 — Dimeric peptide inhibitors of apoptosis proteins

Assigned to Hepagene Therapeutics HK Ltd · Expires 2020-02-13 · 6y expired

What this patent protects

The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by lAPs. In particular the present compounds and compositions may be used to treat lAP-mediated ovarian cancer and hepatitis B infection.

USPTO Abstract

The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by lAPs. In particular the present compounds and compositions may be used to treat lAP-mediated ovarian cancer and hepatitis B infection.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018308116A1
Jurisdiction
AU
Classification
—
Expires
2020-02-13
Drug substance claim
No
Drug product claim
No
Assignee
Hepagene Therapeutics HK Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.